Suppr超能文献

大多数非劣效性试验并非旨在保留活性对照治疗效果。

Most noninferiority trials were not designed to preserve active comparator treatment effects.

机构信息

Schulich School of Medicine and Dentistry, 1151 Richmond St, London, Ontario N6A 5C1, Canada.

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, 90 High Holborn, London WC1V 6LJ, UK.

出版信息

J Clin Epidemiol. 2019 Jun;110:82-89. doi: 10.1016/j.jclinepi.2019.03.003. Epub 2019 Mar 8.

Abstract

OBJECTIVES

To evaluate whether noninferiority trials are designed to adequately preserve the historical treatment effect of their active comparators.

STUDY DESIGN AND SETTING

We reviewed 162 noninferiority trials published in high-impact medical journals. We assessed whether trials were designed to ensure that interventions could only be declared noninferior if they preserved at least 50% of the active comparator's historical treatment effect.

RESULTS

Only 25 of 162 trials (15%) were designed so that interventions could only be declared noninferior if they preserved at least 50% of the active comparator's historical treatment effect. Most trials did not provide evidence that the active comparator was effective (n = 101), provided inadequate evidence (n = 18), or used a noninferiority margin that was too wide (n = 18). In a subset of 61 noninferiority trials which referenced a prior randomized trial or meta-analysis evaluating the active comparator, only 25 (41%) used a noninferiority margin small enough to preserve at least 50% of the active comparator's treatment effect. Overall, 14 of 162 noninferiority trials (9%) would have allowed the intervention to be declared noninferior even if it was worse than either placebo or another historical control.

CONCLUSION

Most noninferiority trials published in major medical journals could allow erroneous declarations of noninferiority.

摘要

目的

评估非劣效性试验是否旨在充分保留其活性对照物的历史治疗效果。

研究设计和设置

我们回顾了在高影响力医学期刊上发表的 162 项非劣效性试验。我们评估了试验的设计是否确保只有在干预措施至少保留活性对照物历史治疗效果的 50%时,才能宣布非劣效性。

结果

只有 162 项试验中的 25 项(15%)设计为只有在干预措施至少保留活性对照物历史治疗效果的 50%时,才能宣布非劣效性。大多数试验没有提供活性对照物有效的证据(n=101),提供的证据不足(n=18),或者使用的非劣效性边界太宽(n=18)。在 61 项参考了先前评估活性对照物的随机试验或荟萃分析的非劣效性试验的子集中,只有 25 项(41%)使用的非劣效性边界足够小,足以保留活性对照物治疗效果的至少 50%。总体而言,162 项非劣效性试验中的 14 项(9%)即使干预措施比安慰剂或另一个历史对照物差,也允许宣布非劣效性。

结论

大多数发表在主要医学期刊上的非劣效性试验可能允许错误地宣布非劣效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验